Literature DB >> 29061541

Personalized Intervention in Monogenic Stone Formers.

Lucas J Policastro1, Subodh J Saggi2, David S Goldfarb3, Jeffrey P Weiss4.   

Abstract

PURPOSE: Treatment of a first-time renal stone consists of acute management followed by medical efforts to prevent stone recurrence. Although nephrolithiasis is roughly 50% heritable, the presence of a family history usually does not affect treatment since most stone disease is regarded as polygenic, ie not attributable to a single gene. Recent evidence has suggested that single mutations could be responsible for a larger proportion of renal stones than previously thought. This intriguing possibility holds the potential to change the management paradigm in stone prevention from metabolically directed therapy to more specific approaches informed by genetic screening and testing. This review synthesizes new findings concerning monogenic kidney stone disease, and provides a concise and clinically useful reference for monogenic causes. It is expected that increased awareness of these etiologies will lead to increased use of genetic testing in recurrent stone formers and further research into the prevalence of monogenic stone disease.
MATERIALS AND METHODS: We assembled a complete list of genes known to cause or influence nephrolithiasis based on recent reviews and commentaries. We then comprehensively searched PubMed® and Google Scholar™ for all research on each gene having a pertinent role in nephrolithiasis. We determined which genes could be considered monogenic causes of nephrolithiasis. One gene, ALPL, was excluded since nephrolithiasis is a relatively minor aspect of the disorder associated with the gene (hypophosphatasia). We summarized selected studies and assembled clinically relevant details.
RESULTS: A total of 27 genes were reviewed in terms of recent findings, mode of inheritance of stone disease, known or supposed prevalence of mutations in the general population of stone patients and specific therapies or considerations.
CONCLUSIONS: There is a distinct opportunity for increased use of genetic testing to improve the lives of pediatric and adult stone patients. Several genes first reported in association with rare disease may be loci for novel mutations, heterozygous disease and forme frustes as causes of stones in the broader population. Cases of idiopathic nephrolithiasis should be considered as potentially having a monogenic basis.
Copyright © 2018 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  genetics; hypercalciuria; kidney calculi; nephrolithiasis; precision medicine

Mesh:

Substances:

Year:  2017        PMID: 29061541      PMCID: PMC5910290          DOI: 10.1016/j.juro.2017.09.143

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  47 in total

Review 1.  Tubular and genetic disorders associated with kidney stones.

Authors:  Nilufar Mohebbi; Pietro Manuel Ferraro; Giovanni Gambaro; Robert Unwin
Journal:  Urolithiasis       Date:  2016-11-28       Impact factor: 3.436

2.  Fourteen monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis.

Authors:  Jan Halbritter; Michelle Baum; Ann Marie Hynes; Sarah J Rice; David T Thwaites; Zoran S Gucev; Brittany Fisher; Leslie Spaneas; Jonathan D Porath; Daniela A Braun; Ari J Wassner; Caleb P Nelson; Velibor Tasic; John A Sayer; Friedhelm Hildebrandt
Journal:  J Am Soc Nephrol       Date:  2014-10-08       Impact factor: 10.121

3.  Urolithiasis and hepatotoxicity are linked to the anion transporter Sat1 in mice.

Authors:  Paul A Dawson; Christopher S Russell; Soohyun Lee; Sarah C McLeay; Jacobus M van Dongen; David M Cowley; Lorne A Clarke; Daniel Markovich
Journal:  J Clin Invest       Date:  2010-02-15       Impact factor: 14.808

Review 4.  Claudins and mineral metabolism.

Authors:  Jianghui Hou
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-07       Impact factor: 2.894

5.  Classical xanthinuria: a rare cause of pediatric urolithiasis.

Authors:  Nurver Akıncı; Adviye Çakıl; Ayşe Öner
Journal:  Turk J Urol       Date:  2013-12

6.  Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy.

Authors:  Peter J Tebben; Dawn S Milliner; Ronald L Horst; Peter C Harris; Ravinder J Singh; Yanhong Wu; John W Foreman; Paul R Chelminski; Rajiv Kumar
Journal:  J Clin Endocrinol Metab       Date:  2012-02-15       Impact factor: 5.958

7.  The Vacuolar H+-ATPase B1 Subunit Polymorphism p.E161K Associates with Impaired Urinary Acidification in Recurrent Stone Formers.

Authors:  Nasser A Dhayat; Andre Schaller; Giuseppe Albano; John Poindexter; Carolyn Griffith; Andreas Pasch; Sabina Gallati; Bruno Vogt; Orson W Moe; Daniel G Fuster
Journal:  J Am Soc Nephrol       Date:  2015-10-09       Impact factor: 10.121

8.  Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosis.

Authors:  Debayan Dasgupta; Mark J Wee; Monica Reyes; Yuwen Li; Peter J Simm; Amita Sharma; Karl-Peter Schlingmann; Marco Janner; Andrew Biggin; Joanna Lazier; Michaela Gessner; Dionisios Chrysis; Shamir Tuchman; H Jorge Baluarte; Michael A Levine; Dov Tiosano; Karl Insogna; David A Hanley; Thomas O Carpenter; Shoji Ichikawa; Bernd Hoppe; Martin Konrad; Lars Sävendahl; Craig F Munns; Hang Lee; Harald Jüppner; Clemens Bergwitz
Journal:  J Am Soc Nephrol       Date:  2014-04-03       Impact factor: 10.121

9.  Heterozygous cystinuria and urinary lithiasis.

Authors:  R Giugliani; I Ferrari; L J Greene
Journal:  Am J Med Genet       Date:  1985-12

Review 10.  Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement.

Authors:  Giovanni Gambaro; Emanuele Croppi; Fredric Coe; James Lingeman; Orson Moe; Elen Worcester; Noor Buchholz; David Bushinsky; Gary C Curhan; Pietro Manuel Ferraro; Daniel Fuster; David S Goldfarb; Ita Pfeferman Heilberg; Bernard Hess; John Lieske; Martino Marangella; Dawn Milliner; Glen M Preminger; Jose' Manuel Reis Santos; Khashayar Sakhaee; Kemal Sarica; Roswitha Siener; Pasquale Strazzullo; James C Williams
Journal:  J Nephrol       Date:  2016-07-25       Impact factor: 3.902

View more
  6 in total

1.  A comparison of the clinical characteristics of pediatric urolithiasis patients with positive and negative molecular diagnoses.

Authors:  Yining Zhao; Xiaoliang Fang; Lei He; Yanjie Fan; Yueyan Li; Guofeng Xu; Yongguo Yu; Hongquan Geng
Journal:  World J Urol       Date:  2022-02-12       Impact factor: 4.226

Review 2.  The genetics of kidney stone disease and nephrocalcinosis.

Authors:  Prince Singh; Peter C Harris; David J Sas; John C Lieske
Journal:  Nat Rev Nephrol       Date:  2021-12-14       Impact factor: 28.314

3.  Absence of the sulfate transporter SAT-1 has no impact on oxalate handling by mouse intestine and does not cause hyperoxaluria or hyperoxalemia.

Authors:  Jonathan M Whittamore; Christine E Stephens; Marguerite Hatch
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-11-01       Impact factor: 4.052

4.  Clinical characterization of primary hyperoxaluria type 3 in comparison with types 1 and 2.

Authors:  Prince Singh; Jason K Viehman; Ramila A Mehta; Andrea G Cogal; Linda Hasadsri; Devin Oglesbee; Julie B Olson; Barbara M Seide; David J Sas; Peter C Harris; John C Lieske; Dawn S Milliner
Journal:  Nephrol Dial Transplant       Date:  2022-04-25       Impact factor: 7.186

Review 5.  Precision medicine in renal stone-formers.

Authors:  Fay Hill; John A Sayer
Journal:  Urolithiasis       Date:  2018-11-20       Impact factor: 3.436

6.  Integration of exome sequencing and metabolic evaluation for the diagnosis of children with urolithiasis.

Authors:  Yining Zhao; Xiaoliang Fang; Yanjie Fan; Yu Sun; Lei He; Maosheng Xu; Guofeng Xu; Yufeng Li; Yunteng Huang; Yongguo Yu; Hongquan Geng
Journal:  World J Urol       Date:  2020-09-16       Impact factor: 4.226

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.